CN Menu
News
News
Release Date
All 2024 2023 2022 2021 2020 2019
Feb, 2023
19
Evergreen awarded as “Digital Health Companies China 50” during MIT Technology Review China Forum
On February 17, the 2022 “Digital Health Companies China 50” list was released at the “2023 MIT Technology Review China Future Health” Summit. As one of the most important benchmarks of digital health, the list consists of 50 outstanding healthcare science and technology companies from six major fields that affect digital health. Among the 50, five promising AI-driven biotech companies including Evergreen Therapeutics, Insilico Medicine, XtalPi were recognized by virtue of their outstanding achievements in the field of digitalization of pharmaceutical R&D.Professor Mohamad Sawan (Fellow of the Canadian Academy of Engineering) address the forum As a US-China based AI-driven biopharmaceutical company, Evergreen Therapeutics is pioneering and highly differentiated in AI drug R&D. Th
Jan, 2023
06
Evergreen Therapeutics and Baidu AI Cloud Signs Cooperation Agreement To Further Deepen its Foundation on AI Research
On January 5, the "cloud-intelligence Integration, In-depth Life Science" activity of life science area "Intelligent Travel" was successfully held in Shenzhen by Baidu AI Cloud. Nearly 100 representatives from scientific research institutes, gene technology, well-known biopharmaceutical enterprises and Internet enterprises attended the meeting. Shenzhen Evergreen Therapeutics Co., Ltd. (hereinafter referred to as "Evergreen Therapeutics" or "Evergreen") As a leader in the field of AI drug research and development in China, was invited to attend this event and serve as the keynote speaker.                                                Dr. Tao Hu, Director of Pharmaco
Dec, 2023
16
Evergreen Therapeutics is named as the “2023 Influential Digital Life and Health Enterprise”.
On December 15th, the 4th China Biomedical Industry Chain Innovation and Transformation International Summit and the 4th China Biomedical Industry Chain Innovation Power List Awards Ceremony were jointly hosted by Hangzhou High-tech Zone Government, Yangtze River Delta Data-driven Innovative Biomedical Industry Chain Alliance, and China Biomedical Industry Chain Innovation Transformation Union in Hangzhou. During the conference, Evergreen Therapeutics was recognized as the "Annual Influential Digital Life Health Enterprise of 2023" on the power list for its exceptional contributions to promoting AI clinical practices domestically in recent years.Conference siteThe conference convened both domestic and international academic scientists, research institution leaders, and distinguished corpor
Sep, 2023
15
Dr. Tom Du and Dr. Charles Lee attended the Hong Kong International Biotechnology Forum and deliver keynote speeches
On September 13th, the four-day BIOHK2023 Hong Kong International Biotechnology Forum kicked off at the Hong Kong Convention and Exhibition Center, Supported by the China Association for Science and Technology, the Ministry of Science and Technology, and the Hong Kong Special Administrative Region Government. BIOHK2023 stands as a preeminent international biotechnology event initiated by the esteemed Hong Kong Biotechnology Association, boasting its status as one of Asia's largest conferences in this field. This gathering convenes numerous distinguished experts and academicians across diverse disciplines, including Nobel laureate Dr. Bruce Beutler, Academician Gao Fu from Chinese Academy of Sciences, Academician Han Jisheng, Dr. Wang Yu from former National Center for Disease Control a
Jun, 2023
06
Evergreen reached strategic partnership with leading CDMO BojiMed
June 5, 2023, BojiMed Pharmaceutical Technology Co., Ltd. (stock code: 300404, hereinafter referred to as "BOJIMED"), a well-established domestic CRO listed company, and Shenzhen Evergreen Therapeutics Co. , Ltd. (hereinafter referred to as "Evergreen") Signing a strategic cooperation agreement , the two parties adhere to the principle of "complementary advantages, mutual benefit and win-win", use artificial intelligence (AI) to carry out strategic cooperation in the field of clinical trials, and jointly promote the efficient clinical development and commercialization of innovative drugs in multiple disease fields. By complementing each other's strengths and leveraging the advantages of their respective expert teams, AI can be used to solve bottleneck issues that affect drug research a
May, 2023
07
Evergreen is named as "China's Innovative Biotech Top100" and won "AI Pharmaceutical Value Award"
From May 5th to 7th, the 7th Future Medical Top 100 Conference sponsored by VB100, VBdate, and VCBeat Research was grandly held at the Zhangjiang Science Hall in Shanghai. The conference received strong support from the Shanghai Pudong District Government and Zhangjiang Group, and brought together many Chinese and foreign academicians and experts in various fields, including the internationally renowned scientist Professor Robert Langer . Professor Robert Langer’s speech As an expert with many years of experience in pharmaceutical technology transfer, Dr. Tom Du, chairman of Evergreen, hosted a roundtable forum with listed pharmaceutical company in the United States, innovative pharmaceutical companies in China, well-known investment institutions, and pharmaceutical experts from